Liaoning Chengda Biotechnology (688739.SH): Benxi subsidiary passes drug GMP compliance inspection.

Liaoning Chengda Biotechnology (688739.SH) announced that its wholly-owned subsidiary, Liaoning Chengda Biotechnology (Benxi) Co., Ltd. (referred to as "Benxi Subsidiary"), recently received a "Notice of Results of On-Site Inspection of Drug GMP Compliance" (No. Liao26010013) issued by the Liaoning Provincial Drug Administration. The freeze-dried human rabies vaccine (human diploid cell) produced at the production base of the Benxi Subsidiary has passed the compliance inspection of the Drug Production Quality Management Specification. The passing of the drug GMP compliance inspection by the Benxi Subsidiary indicates that its production base meets the commercial production conditions for freeze-dried human rabies vaccine (human diploid cell) and that its production quality management system complies with relevant drug regulatory requirements. This inspection is conducive to further improving the company's vaccine production system and quality control capabilities, ensuring stable product supply, continuously enhancing the company's core competitiveness and advantageous market position in the field of human rabies vaccine, and is of great positive significance for the company's future business development.